Corporate - Media & Press - Press Release
Arrayit Technology Purchased by Johns Hopkins University to Study Rheumatoid Arthritis
Medical Center Uses Arrayit Protein Microarray Platform to Identify Biomarkers for Autoimmune Diseases
Source: Arrayit Corporation
On Thursday November 18, 2009, 7:00 am EDT
SUNNYVALE, CA -- (Marketwire) - 11/18/09 - Arrayit Corporation (OTCBB: ARYC) announced today that the High Throughput Biology Center at Johns Hopkins University School of Medicine in Baltimore Maryland purchased Arrayit's proprietary technology to discover biomarkers for autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, autoimmune hepatitis, lupus, and others.
Arrayit's patented NanoPrint microarray platform deposits nanoliter quantities of proteins onto glass substrates to create the chips.
Arrayit NanoPrint platforms have been installed at other major research and diagnostics centers including Harvard University in Massachusetts, Sandia National Laboratories in New Mexico, Scripps Research Institute in Florida, The Biodesign Institute in Arizona, and Mount Sinai School of Medicine in New York City.
About Arrayit Corporation
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 10,000 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.
Safe Harbor Statement
Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009, Form 10-Q/A for the fiscal second quarter ended June 30, 2009 and Form 10-Q/A for the fiscal third quarter ended September 30, 2009.
Copyright 1993-2018 Arrayit Corporation. All rights reserved.